| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
|
N Engl J Med
|
2015
|
7.51
|
|
2
|
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
|
Lancet Oncol
|
2012
|
5.32
|
|
3
|
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
|
J Clin Oncol
|
2005
|
4.64
|
|
4
|
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.
|
Cancer Res
|
2009
|
4.16
|
|
5
|
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
|
J Clin Oncol
|
2008
|
2.77
|
|
6
|
Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls.
|
Int J Epidemiol
|
2009
|
2.32
|
|
7
|
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.
|
Clin Cancer Res
|
2004
|
2.28
|
|
8
|
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
|
J Clin Oncol
|
2007
|
2.19
|
|
9
|
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
|
J Clin Oncol
|
2013
|
2.11
|
|
10
|
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
|
Cancer
|
2010
|
2.10
|
|
11
|
Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.
|
Clin Cancer Res
|
2009
|
1.94
|
|
12
|
Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.
|
J Clin Oncol
|
2002
|
1.60
|
|
13
|
Interferon alfa-2a for melanoma metastases.
|
Lancet
|
2002
|
1.55
|
|
14
|
A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes.
|
Int J Cancer
|
2009
|
1.51
|
|
15
|
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.
|
J Immunother
|
2013
|
1.48
|
|
16
|
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
|
Nat Rev Clin Oncol
|
2013
|
1.46
|
|
17
|
The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
|
J Clin Pharmacol
|
2014
|
1.45
|
|
18
|
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
|
Urology
|
2013
|
1.44
|
|
19
|
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.
|
Blood
|
2008
|
1.43
|
|
20
|
Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.
|
J Immunother
|
2011
|
1.41
|
|
21
|
Pigmentary characteristics and moles in relation to melanoma risk.
|
Int J Cancer
|
2005
|
1.40
|
|
22
|
Tracking antigen-driven responses by flow cytometry: monitoring proliferation by dye dilution.
|
Cytometry A
|
2008
|
1.33
|
|
23
|
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
|
Eur J Cancer
|
2011
|
1.26
|
|
24
|
Expressive disclosure and health outcomes in a prostate cancer population.
|
Int J Psychiatry Med
|
2002
|
1.17
|
|
25
|
Exposure to sunlamps, tanning beds, and melanoma risk.
|
Cancer Causes Control
|
2008
|
1.11
|
|
26
|
Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850).
|
Clin Cancer Res
|
2006
|
1.10
|
|
27
|
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference.
|
Clin Cancer Res
|
2007
|
1.07
|
|
28
|
Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme.
|
Neuro Oncol
|
2011
|
1.07
|
|
29
|
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.
|
Cancer
|
2013
|
1.05
|
|
30
|
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
|
Cancer
|
2006
|
1.05
|
|
31
|
A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival.
|
Clin Cancer Res
|
2010
|
1.05
|
|
32
|
VISTA is an immune checkpoint molecule for human T cells.
|
Cancer Res
|
2014
|
1.03
|
|
33
|
Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma.
|
J Clin Invest
|
2011
|
1.03
|
|
34
|
A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.
|
J Immunother
|
2011
|
1.02
|
|
35
|
Multiple primary melanoma: two-year results from a population-based study.
|
Arch Dermatol
|
2006
|
1.00
|
|
36
|
The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?
|
Br J Clin Pharmacol
|
2008
|
0.99
|
|
37
|
Clinical electron paramagnetic resonance (EPR) oximetry using India ink.
|
Adv Exp Med Biol
|
2010
|
0.98
|
|
38
|
Immunotherapy for the treatment of glioblastoma.
|
Cancer J
|
2012
|
0.93
|
|
39
|
Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.
|
J Clin Oncol
|
2006
|
0.92
|
|
40
|
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
|
Cancer
|
2008
|
0.92
|
|
41
|
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
|
Oncology
|
2010
|
0.91
|
|
42
|
Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.
|
Cancer Lett
|
2009
|
0.89
|
|
43
|
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer.
|
Clin Cancer Res
|
2007
|
0.88
|
|
44
|
Multiparameter precursor analysis of T-cell responses to antigen.
|
J Immunol Methods
|
2003
|
0.87
|
|
45
|
Been there, not done that--melanoma in the age of molecular therapy.
|
N Engl J Med
|
2011
|
0.87
|
|
46
|
Self-recognition and tumor response to immunotherapy.
|
J Clin Oncol
|
2005
|
0.87
|
|
47
|
Primary melanoma of the spinal cord: a case report, molecular footprint, and review of the literature.
|
J Clin Oncol
|
2011
|
0.87
|
|
48
|
Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).
|
Med Oncol
|
2003
|
0.86
|
|
49
|
Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-α and dendritic cell vaccine.
|
PLoS One
|
2012
|
0.86
|
|
50
|
Program to support safe administration of oral chemotherapy.
|
J Oncol Pract
|
2006
|
0.85
|
|
51
|
Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032.
|
Pigment Cell Melanoma Res
|
2014
|
0.85
|
|
52
|
Modulation of antitumor immune responses by hematopoietic cytokines.
|
Cancer
|
2003
|
0.85
|
|
53
|
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
|
J Immunother
|
2005
|
0.84
|
|
54
|
Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients.
|
Clin Immunol
|
2005
|
0.84
|
|
55
|
Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma.
|
Clin Genitourin Cancer
|
2007
|
0.84
|
|
56
|
Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF).
|
Prostate
|
2006
|
0.83
|
|
57
|
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma.
|
Invest New Drugs
|
2013
|
0.82
|
|
58
|
The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells.
|
Transfusion
|
2014
|
0.82
|
|
59
|
Regulatory T-cells and associated pathways in metastatic renal cell carcinoma (mRCC) patients undergoing DC-vaccination and cytokine-therapy.
|
PLoS One
|
2012
|
0.81
|
|
60
|
Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression (United States).
|
Cancer Causes Control
|
2002
|
0.81
|
|
61
|
Merkel cell polyomavirus and extrapulmonary small cell carcinoma.
|
Oncol Lett
|
2013
|
0.80
|
|
62
|
Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications.
|
J Immunol Methods
|
2002
|
0.79
|
|
63
|
Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma.
|
Biol Blood Marrow Transplant
|
2012
|
0.79
|
|
64
|
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.
|
J Clin Oncol
|
2010
|
0.79
|
|
65
|
Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected.
|
Cytotherapy
|
2010
|
0.79
|
|
66
|
Dye dilution proliferation assay: application of the DDPA to identify tumor-specific T cell precursor frequencies in clinical trials.
|
Immunol Invest
|
2007
|
0.79
|
|
67
|
The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.
|
Melanoma Res
|
2016
|
0.77
|
|
68
|
Is pediatric melanoma always malignant?
|
Cancer
|
2013
|
0.77
|
|
69
|
Novel mobilization strategies to enhance autologous immune effector cells in multiple myeloma.
|
Front Biosci (Elite Ed)
|
2011
|
0.77
|
|
70
|
Therapeutic vaccines in renal cell carcinoma.
|
Therapy
|
2011
|
0.77
|
|
71
|
The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-1b in a multiple-dose phase I study in patients with advanced cancer.
|
Cancer Chemother Pharmacol
|
2002
|
0.76
|
|
72
|
A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.
|
J Chemother
|
2013
|
0.76
|
|
73
|
Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.
|
J Urol
|
2004
|
0.76
|
|
74
|
Genetic profiles of plasmacytoid (BDCA-4 expressing) DC subtypes-clues to DC subtype function in vivo.
|
Exp Hematol Oncol
|
2013
|
0.76
|
|
75
|
Vaccine-based immunotherapy for glioblastoma.
|
CNS Oncol
|
2013
|
0.75
|
|
76
|
Indoleamine-2,3-dioxygenase enzyme expression and activity in polarized dendritic cells.
|
Cytotherapy
|
2009
|
0.75
|
|
77
|
Use and abuse of statistics in evidence-based medicine.
|
J Clin Oncol
|
2002
|
0.75
|
|
78
|
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.
|
J Immunother
|
2007
|
0.75
|
|
79
|
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
|
J Immunother
|
2007
|
0.75
|
|
80
|
Factors associated with atypical moles in New Hampshire, USA.
|
Acta Derm Venereol
|
2007
|
0.75
|